Eradication of systemic B-cell tumors by genetically targeted human T lymphocytes co-stimulated by CD80 and interleukin-15 - PubMed (original) (raw)
doi: 10.1038/nm827. Epub 2003 Feb 10.
Affiliations
- PMID: 12579196
- DOI: 10.1038/nm827
Eradication of systemic B-cell tumors by genetically targeted human T lymphocytes co-stimulated by CD80 and interleukin-15
Renier J Brentjens et al. Nat Med. 2003 Mar.
Abstract
The genetic transfer of antigen receptors provides a means to rapidly generate autologous tumor-reactive T lymphocytes. However, recognition of tumor antigens by cytotoxic T cells is only one step towards effective cancer immunotherapy. Other crucial biological prerequisites must be fulfilled to expand tumor-reactive T cells that retain a functional phenotype, including in vivo cytolytic activity and the ability to travel to tumor sites without prematurely succumbing to apoptosis. We show that these requirements are met by expanding peripheral blood T cells genetically targeted to the CD19 antigen in the presence of CD80 and interleukin-15 (IL-15). T cells expanded in the presence of IL-15 uniquely persist in tumor-bearing severe combined immunodeficiency (SCID)-Beige mice and eradicate disseminated intramedullary tumors. Their anti-tumor activity is further enhanced by in vivo co-stimulation. In addition, transduced T cells from patients with chronic lymphocytic leukemia (CLL) effectively lyse autologous tumor cells. These findings strongly support the clinical feasibility of this therapeutic strategy.
Comment in
- Cancer T cell therapy expands.
Becknell B, Caligiuri MA. Becknell B, et al. Nat Med. 2003 Mar;9(3):257-8. doi: 10.1038/nm0303-257. Nat Med. 2003. PMID: 12612567 No abstract available.
Similar articles
- Genetically targeted T cells eradicate systemic acute lymphoblastic leukemia xenografts.
Brentjens RJ, Santos E, Nikhamin Y, Yeh R, Matsushita M, La Perle K, Quintás-Cardama A, Larson SM, Sadelain M. Brentjens RJ, et al. Clin Cancer Res. 2007 Sep 15;13(18 Pt 1):5426-35. doi: 10.1158/1078-0432.CCR-07-0674. Epub 2007 Sep 12. Clin Cancer Res. 2007. PMID: 17855649 - IL-12-secreting CD19-targeted cord blood-derived T cells for the immunotherapy of B-cell acute lymphoblastic leukemia.
Pegram HJ, Purdon TJ, van Leeuwen DG, Curran KJ, Giralt SA, Barker JN, Brentjens RJ. Pegram HJ, et al. Leukemia. 2015 Feb;29(2):415-22. doi: 10.1038/leu.2014.215. Epub 2014 Jul 9. Leukemia. 2015. PMID: 25005243 Free PMC article. - A novel approach to cancer immunotherapy: tumor cells decorated with CD80 generate effective antitumor immunity.
Singh NP, Yolcu ES, Taylor DD, Gercel-Taylor C, Metzinger DS, Dreisbach SK, Shirwan H. Singh NP, et al. Cancer Res. 2003 Jul 15;63(14):4067-73. Cancer Res. 2003. PMID: 12874008 - Chimeric antigen receptor engineering: a right step in the evolution of adoptive cellular immunotherapy.
Figueroa JA, Reidy A, Mirandola L, Trotter K, Suvorava N, Figueroa A, Konala V, Aulakh A, Littlefield L, Grizzi F, Rahman RL, Jenkins MR, Musgrove B, Radhi S, D'Cunha N, D'Cunha LN, Hermonat PL, Cobos E, Chiriva-Internati M. Figueroa JA, et al. Int Rev Immunol. 2015 Mar;34(2):154-87. doi: 10.3109/08830185.2015.1018419. Int Rev Immunol. 2015. PMID: 25901860 Review. - An unmet need: Harmonization of IL-7 and IL-15 combination for the ex vivo generation of minimally differentiated T cells.
Marton C, Mercier-Letondal P, Galaine J, Godet Y. Marton C, et al. Cell Immunol. 2021 May;363:104314. doi: 10.1016/j.cellimm.2021.104314. Epub 2021 Feb 23. Cell Immunol. 2021. PMID: 33677140 Review.
Cited by
- Recent advancements in improving the efficacy and safety of chimeric antigen receptor (CAR)-T cell therapy for hepatocellular carcinoma.
Ren T, Huang Y. Ren T, et al. Naunyn Schmiedebergs Arch Pharmacol. 2024 Sep 24. doi: 10.1007/s00210-024-03443-7. Online ahead of print. Naunyn Schmiedebergs Arch Pharmacol. 2024. PMID: 39316087 Review. - Artificial antigen-presenting cells: the booster for the obtaining of functional adoptive cells.
Li J, Zhou W, Wang W. Li J, et al. Cell Mol Life Sci. 2024 Aug 31;81(1):378. doi: 10.1007/s00018-024-05412-y. Cell Mol Life Sci. 2024. PMID: 39215816 Free PMC article. Review. - Fate induction in CD8 CAR T cells through asymmetric cell division.
Lee CS, Chen S, Berry CT, Kelly AR, Herman PJ, Oh S, O'Connor RS, Payne AS, Ellebrecht CT. Lee CS, et al. Nature. 2024 Sep;633(8030):670-677. doi: 10.1038/s41586-024-07862-7. Epub 2024 Aug 28. Nature. 2024. PMID: 39198645 Free PMC article. - Manufacturing CD20/CD19-targeted iCasp9 regulatable CAR-TSCM cells using a Quantum pBac-based CAR-T engineering system.
Chang PS, Chen YC, Hua WK, Hsu JC, Tsai JC, Huang YW, Kao YH, Wu PH, Wang PN, Chang YF, Chang MC, Chang YC, Jian SL, Lai JS, Lai MT, Yang WC, Shen CN, Wen KK, Wu SC. Chang PS, et al. PLoS One. 2024 Aug 27;19(8):e0309245. doi: 10.1371/journal.pone.0309245. eCollection 2024. PLoS One. 2024. PMID: 39190688 Free PMC article. - CAR-T and CAR-NK as cellular cancer immunotherapy for solid tumors.
Peng L, Sferruzza G, Yang L, Zhou L, Chen S. Peng L, et al. Cell Mol Immunol. 2024 Oct;21(10):1089-1108. doi: 10.1038/s41423-024-01207-0. Epub 2024 Aug 12. Cell Mol Immunol. 2024. PMID: 39134804 Free PMC article. Review.
Publication types
MeSH terms
Substances
Grants and funding
- AI44926/AI/NIAID NIH HHS/United States
- CA-08748/CA/NCI NIH HHS/United States
- P30 CA008748/CA/NCI NIH HHS/United States
- CA-83084/CA/NCI NIH HHS/United States
- CA-86438/CA/NCI NIH HHS/United States
- CA-59350/CA/NCI NIH HHS/United States
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous